GMAB Valuation

Genmab A/S

Add to Watchlist

Advanced Chart

28.710

+0.1(0.350%)1D

GMAB Relative Valuation

GMAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GMAB is overvalued; if below, it's undervalued.

Historical Valuation

Genmab A/S (GMAB) is now in the Fair zone, suggesting that its current forward PE ratio of 20.19 is considered Fairly compared with the five-year average of 40.43. The fair price of Genmab A/S (GMAB) is between 18.58 to 81.73 according to relative valuation methord.

Relative Value

Fair Zone

18.58-81.73

Current Price：28.61

Fair

20.19

Trailing

Forward

7.78

EV/EBITDA

Genmab A/S. (GMAB) has a current EV/EBITDA of 7.78. The 5-year average EV/EBITDA is 29.41. The thresholds are as follows: Strongly Undervalued below -23.53, Undervalued between -23.53 and 2.94, Fairly Valued between 55.87 and 2.94, Overvalued between 55.87 and 82.34, and Strongly Overvalued above 82.34. The current Forward EV/EBITDA of 7.78 falls within the Historic Trend Line -Fairly Valued range.

8.92

EV/EBIT

Genmab A/S. (GMAB) has a current EV/EBIT of 8.92. The 5-year average EV/EBIT is 28.13. The thresholds are as follows: Strongly Undervalued below -8.32, Undervalued between -8.32 and 9.90, Fairly Valued between 46.35 and 9.90, Overvalued between 46.35 and 64.57, and Strongly Overvalued above 64.57. The current Forward EV/EBIT of 8.92 falls within the Undervalued range.

28.61

Genmab A/S. (GMAB) has a current PS of 28.61. The 5-year average PS is 11.13. The thresholds are as follows: Strongly Undervalued below -14.13, Undervalued between -14.13 and -1.50, Fairly Valued between 23.76 and -1.50, Overvalued between 23.76 and 36.40, and Strongly Overvalued above 36.40. The current Forward PS of 28.61 falls within the Overvalued range.

17.01

P/OCF

Genmab A/S. (GMAB) has a current P/OCF of 17.01. The 5-year average P/OCF is 33.71. The thresholds are as follows: Strongly Undervalued below -2.09, Undervalued between -2.09 and 15.81, Fairly Valued between 51.61 and 15.81, Overvalued between 51.61 and 69.51, and Strongly Overvalued above 69.51. The current Forward P/OCF of 17.01 falls within the Historic Trend Line -Fairly Valued range.

15.86

P/FCF

Genmab A/S. (GMAB) has a current P/FCF of 15.86. The 5-year average P/FCF is 38.48. The thresholds are as follows: Strongly Undervalued below 3.58, Undervalued between 3.58 and 21.03, Fairly Valued between 55.93 and 21.03, Overvalued between 55.93 and 73.38, and Strongly Overvalued above 73.38. The current Forward P/FCF of 15.86 falls within the Undervalued range.

Genmab A/S (GMAB) has a current Price-to-Book (P/B) ratio of 0.33. Compared to its 3-year average P/B ratio of 3.99 , the current P/B ratio is approximately -91.67% higher. Relative to its 5-year average P/B ratio of 5.47, the current P/B ratio is about -93.94% higher. Genmab A/S (GMAB) has a Forward Free Cash Flow (FCF) yield of approximately 6.25%. Compared to its 3-year average FCF yield of 5.14%, the current FCF yield is approximately 21.47% lower. Relative to its 5-year average FCF yield of 3.97% , the current FCF yield is about 57.58% lower.

0.33

P/B

Median3y

3.99

Median5y

5.47

6.25

FCF Yield

Median3y

5.14

Median5y

3.97

Competitors Valuation Multiple

The average P/S ratio for GMAB's competitors is 108.03, providing a benchmark for relative valuation. Genmab A/S Corp (GMAB) exhibits a P/S ratio of 28.61, which is -73.52% above the industry average. Given its robust revenue growth of 149.02%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Vertex Pharmaceuticals Inc

Bristol-Myers Squibb Co

Performance Decomposition

Market capitalization of GMAB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of GMAB in the past 1 year is driven by Unknown.